Table 3.
Frequency of adverse drug events observed during MDR treatment, Pham Ngoc Thach hospital, 2010
| Type of adverse eventa | Total | Mildb | Moderatec | Severed | No information | |
|---|---|---|---|---|---|---|
| n | % | |||||
| Total | 226 | 100.0 | 78 | 32 | 25 | 91 |
| Arthralgia/joint pain | 81 | 35.8 | 25 | 16 | 7 | 33 |
| Gastrointestinal | 32 | 14.2 | 18 | 2 | 0 | 12 |
| Ototoxicity | 19 | 8.4 | 8 | 3 | 4 | 4 |
| Cutaneous reaction | 15 | 6.6 | 4 | 4 | 0 | 7 |
| Giddiness | 13 | 5.8 | 2 | 1 | 0 | 10 |
| Psychiatric symptoms | 10 | 4.4 | 5 | 1 | 3 | 1 |
| Hepatitis | 7 | 3.1 | 1 | 2 | 4 | 0 |
| Peripheral neuropathy | 7 | 3.1 | 3 | 1 | 0 | 3 |
| Renal toxicity | 5 | 2.2 | 2 | 0 | 3 | 0 |
| Visual symptoms | 5 | 2.2 | 4 | 0 | 0 | 1 |
| Insomnia | 5 | 2.2 | 0 | 0 | 0 | 5 |
| Hypothyroidism | 3 | 1.3 | 0 | 2 | 1 | 0 |
| Central nervous system | 1 | 0.4 | 0 | 0 | 0 | 1 |
| Others | 23 | 10.2 | 6 | 0 | 3 | 14 |
a An individual patient could have had more than 1 adverse event during the MDR treatment period
b Mild: the drug was continued at the same dose, with or without ancillary drug prescribed, e.g., reassurance
c Moderate: drug was continued at a reduced dose, with an ancillary drug prescribed
d Severe: drug was changed or stopped and/or all medical treatment was stopped